| [1] |
杜奕奇，蔡全才，廖专，等. 中国早期胃癌筛查流程专家共识意见(草案)(2017年，上海)[J]. 胃肠病学，2018，23(2)：92-97.
|
| [2] |
Mansour-ghanaei F, Joukar F, Rajpout Y, et al. Screening of precancerous gastric lesions by serum pepsinogen, gastrin-17, anti-helicobacter pylori and anti-CagA antibodies in dyspeptic patients over 50 years old in Guilan Province, north of Iran[J]. Asian Pac J Cancer Prev, 2014, 15(18): 7635-7638.
|
| [3] |
Wang K, Liang Q, Li X, et al. MDGA2 is a novel tumour suppressor cooperating with DMAP1 in gastric cancer and is associated with disease outcome[J]. Gut, 2016, 65(10): 1619-1631.
|
| [4] |
Waldum HL, Hauso Ø, Sørdal ØF, et al. Gastrin May Mediate the Carcinogenic Effect of Helicobacter pylori Infection of the Stomach[J]. Dig Dis Sci, 2015, 60(6): 1522-1527.
|
| [5] |
薛辉，辛凤池，穆素恩，等. 血清胃蛋白酶原联合G-17对萎缩性胃炎及胃癌早期诊断价值[J]. 现代生物医学进展，2017，17(11)：2119-2122.
|
| [6] |
Xu W, Chen G, Shao Y, et al. Gastrin acting on the cholecystokinin2 receptor induces cyclooxygenase-2 expression through JAK2/STAT3/PI3K/Akt pathway in human gastric cancer cells[J]. Cancer Letters, 2013, 332(1): 11-18.
|
| [7] |
Tang E, Wang Y, Liu T, et al. Gastrin promotes angiogenesis by activating HIF-1α/β-catenin/VEGF signaling in gastric cancer[J]. Gene, 2019, 704: 42-48.
|
| [8] |
朱春平，赵建业，申晓军，等. 血清胃泌素-17联合胃蛋白酶原检测对胃癌诊断价值的多中心临床研究[J]. 中华消化内镜杂志，2017，34(1)：19-23.
|
| [9] |
Chen C, HsuY, Lee C, et al. Central Obesity and H. pylori Infection Influence Risk of Barrett′s Esophagus in an Asian Population[J]. PloS One, 2016, 11(12): e167815.
|
| [10] |
Akazawa Y, Isomoto H, Matsushima K, et al. Endoplasmic reticulum stress contributes to Helicobacter pylori VacA-induced apoptosis[J]. PloS One, 2013, 8(12): e82322.
|
| [11] |
Yang F, Xu Y, Liu C, et al. NF-κB/miR-223-3p/ARID1A axis is involved in Helicobacter pylori CagA-induced gastric carcinogenesis and progression[J]. Cell Death Dis, 2018, 9(1): 12.
|
| [12] |
姜静宜，孙丽萍. 胃黏膜"血清学活检"与胃糜烂溃疡性疾病[J]. 胃肠病学和肝病学杂志，2015，24(2)：140-142.
|
| [13] |
张苗苗，赵志鹏，李晓晨，等. 幽门螺杆菌抗体分型检测及分型与胃部疾病的相关性分析[J]. 标记免疫分析与临床，2020，27(8)：1305-1309.
|
| [14] |
Correa P, Piazuelo MB. The gastric precancerous cascade[J]. J Dig Dis, 2012, 13(1): 2-9.
|
| [15] |
Vannella L, Lahner E, Osborn J, et al. Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis[J]. Aliment Pharmaclol Ther, 2010, 31(9): 1042-1050.
|
| [16] |
Korstanje A, den Hartog G, Biemond I, et al. The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature[J]. Scand J Gastroenterol, 2002, 236 (Suppl): 22-26.
|
| [17] |
Bornschein J, Selgrad M, Wex T, et al. Serological assessment of gastric mucosal atrophy in gastric cancer[J]. BMC Gastroenterol, 2012, 12(1): 10.
|
| [18] |
Shafaghi A, Mansour-ghanaei F, Joukar F, et al. Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions[J]. Asian Pac J Cancer Prev, 2013, 14(6): 3931-3936.
|
| [19] |
Adamu MA, Weck MN, Rothenbache D, et al. Incidence and risk factors for the development of chronic atrophic gastritis: five year follow-up of a population-based cohort study[J]. Int J Cancer, 2011, 128(7): 1652-1658.
|
| [20] |
Varis K, Sipponen P, Laxen F, et al. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia.Helsinki Gastritis Study Group[J]. Scand J Gastroenterol, 2000, 35(9): 950-956.
|
| [21] |
Mlki K. Gastric cancer screening using the serum pepsinogen test method[J]. Gastric Cancer, 2006, 9(4): 245-253.
|
| [22] |
Sierra R, Une C, Ramirez V, et al.Association of serum pepsinogen with atrophic body gastritis in Costa Rica[J]. Clin Exp Med, 2006, 6(2): 72-78.
|
| [23] |
Sun L, Tu H, Liu J, et al. A comprehensive evaluation of fasting serum gastrin-17 as a predictor of diseased stomach in Chinese population[J]. Scand J Gastroenterol, 2014, 49(10): 1164-1172.
|
| [24] |
Maddalo G, Spolverato Y, Rugge M, et al. Gastrin: from pathophysiology to cancer prevention and treatment[J]. Eur J Cancer Prev, 2014, 23(4): 258-263.
|
| [25] |
Väänänen H, Vauhkonem M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study[J]. Eur J Gastroenterol Hepatol, 2003, 15(8): 885-891.
|
| [26] |
Lorente S, Doiz O, Serrano MT, et al. Helicobacter pylori stimulates pepsinogen secretion from isolated human peptic cells[J]. Gut, 2002, 50(1): 13-18.
|
| [27] |
Ohkusa T, Miwa H, Nomura T, et al. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylori-negative patients[J]. Alim Pharmacol Ther, 2004, 20(s1): 25-32.
|
| [28] |
Sun LP, Gong YH, Wang L, et al. Serum pepsinogen levels and their influencing factors: a population-based study in 6990 Chinese from North China[J]. World J Gastroenterol, 2007, 13(48): 6562-6567.
|
| [29] |
Venerito M, Varbanova M, Röhl F, et al. Oxyntic gastric atrophy inHelicobacter pylori gastritis is distinct from autoimmune gastritis[J]. J Clin Pathol, 2016, 69(8): 677-685.
|
| [30] |
Gong Y, Wei W, Jing WL, et al. Helicobacter pylori Infection Status Correlates with Serum Parameter Levels Responding to Multi-organ Functions[J]. Dig Dis Sci, 2015, 60(6): 1748-1754.
|
| [31] |
Wroblewskil E, Pritchard DM, Carter S, et al. Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression[J]. Biochem J, 2002, 365(Pt 3): 873-879.
|
| [32] |
Mizuno S, Miki I, Ishida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis[J]. Dig Dis Sci, 2010, 55(11): 3132-3137.
|
| [33] |
Pradeep A, Sharma C, Sathyanarayana P, et al. Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells[J]. Oncogene, 2004, 23(20): 3689-3699.
|
| [34] |
Wang TC, Dangler CA, Chen D, et al.Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer[J]. Gastroenterology, 2000, 118(1): 36-47.
|
| [35] |
Watabe H, Mittsushima T, Yamaji Y, et al. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study[J]. Gut, 2005, 54(6): 764-768.
|
| [36] |
SIPPONEN P, RANTA P, HELSKE T, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study[J]. Scand J Gastroenterol, 2002, 37(7): 785-791.
|
| [37] |
Tu H, Sun L, Dong X, et al. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study[J]. Am J Gastroenterol, 2017, 112(5): 704-715.
|